**SUPPLEMENTARY DATA**

Supplementary Figure 1: RAPID-axSpA trial design to Week 204



aLoading dose of PBO. CZP: certolizumab pegol; LD: Loading Dose; Q2W: every other week; Q4W: every 4 weeks; PBO: placebo; Wk: week.

 Supplementary Table 1: Number of images available for each imaging modality.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Week 0** | **Week 12** | **Week 96** | **Week 204** |
|  | **axSpA** | **AS** | **nr-axSpA** | **axSpA** | **AS** | **nr-axSpA** | **axSpA** | **AS** | **nr-axSpA** | **axSpA** | **AS** | **nr-axSpA** |
| **Berlin** |  153 | 92 |  61 |  149 |  90 | 59 |  120 | 74 | 46 |  82 | 50 | 32 |
| **SPARCC** |  151 | 91 | 60 | 144 | 84 | 60 |  120 | 73 | 47 |  72 | 41 | 31 |
| **mSASSS** | 190 | 110 | 80 | NA | NA | NA | 141 | 86 | 55 | 106 | 64 | 42 |
| **SI joint radiograph** | 273 | 180 | 93 | NA | NA  | NA  |  NA | NA  |  NA | 137 | 101 | 36 |

Data are presented for all patients who received ≥1 dose CZP at any point in the trial (n=315). SPARCC: Spondyloarthritis Research Consortium for Canada; mSASSS: Modified Stoke Ankylosing Spondylitis Spine Score; SI: sacroiliac; NA: Not Applicable.

Supplementary Table 2: Number of axSpA patients with mSASSS readings at baseline, Week 96 and Week 204.

|  |  |
| --- | --- |
| **mSASSS reading** |  |
| **Baseline** | **Week 96** | **Week 204** | **n** |
| X | X | X | 93 |
| X |  |  | 45 |
| X | X |  | 45 |
| X |  | X | 10 |
|  | X | X | 3 |

Data are presented for all patients who received ≥1 mSASSS reading during the trial (n=196).

**Supplementary Table 3:** ASDAS outcomes for patients with and without mSASSS readings at all timepoints.

|  |  |  |  |
| --- | --- | --- | --- |
| **AS Population** | **n** | **Mean ASDAS (LOCF)** | **Mean ASDAS (observed)** |
| **BL** | **Wk12\*** | **Wk96** | **Wk204** | **Wk96** | **Wk204** |
| **Group** | **mSASSS available** | **Mean** | **Mean** | **Change from BL** | **Mean** | **Change from BL** | **Mean** | **Change from BL** | **Nobs** | **Mean** | **Nobs** | **Mean** |
| 1 | BL, Wk96, Wk204 | 59 | 4.07 | 1.95 | -1.97 | 1.98 | -2.09 | 2.08 | -1.98 | 59 | 1.98 | 58 | 2.05 |
| 2 | BL, Wk96 | 26 | 3.70 | 2.22 | -1.59 | 1.96 | -1.73 | 1.99 | -1.71 | 25 | 1.84 | 8 | 2.10 |
| 3 | BL, Wk204 | 4 | 4.26 | 2.76 | -1.50 | 1.79 | -2.47 | 1.28 | -2.98 | 2 | 2.16 | 4 | 1.28 |
| 4 | Only once | 23 | 4.01 | 2.32 | -1.49 | 1.99 | -2.02 | 2.12 | -1.89 | 6 | 1.53 | 4 | 1.87 |

\*Week 0 CZP 200 mg + 400 mg group. ASDAS: Ankylosing spondylitis diseases activity score; mSASSS: modified Stoke Ankylosing Spondylitis Spinal Score; AS: ankylosing spondylitis; LOCF: last observation carried forward; BL: baseline; Wk: week; Nobs: number observed.

**Supplementary Figure 2:** Radiographic imaging results for the spine in AS and nr-axSpA patients with images available at baseline and Weeks 96 and 204.

****

All CZP-treated patients include those re-randomised to placebo from baseline; 200 mg + 400 mg dose groups were combined. mSASSS: modified Stoke Ankylosing Spondylitis Spinal Score; LS: least squares; AS: ankylosing spondylitis; nr-axSpA: non-radiographic spondyloarthritis.